Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009

Vaccine

Volumn 30, Issue 28, 2012, Pages 4240-4248

  Chen, Wilbur H ^a   Winokur, Patricia L ^b,c   Edwards, Kathryn M ^d   Jackson, Lisa A ^e   Wald, Anna ^f   Walter, Emmanuel B ^g   Noah, Diana L ^h   Wolff, Mark ⁱ   Kotloff, Karen L ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SOUTHERN RESEARCH INSTITUTE   (United States)

ⁱ EMMES CORPORATION   (United States)

Author keywords

Influenza; Pandemic; Vaccines

Indexed keywords

HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MALAISE; MALE; MASS IMMUNIZATION; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PANDEMIC; PHASE 2 CLINICAL TRIAL; PLANNING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TENDERNESS; UNITED STATES; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; UNITED STATES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84861669566     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.044     Document Type: Article

References (31)

1. World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html.
2. The President's Council of Advisors on Science and Technology Executive Report. U.S. Preparations for the 2009-H1N1 influenza; August 7, 2009.
3. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 2006, 354(March (13)):1343-1351.
4. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. New England Journal of Medicine 2009, 361(December (25)):2405-2413.
5. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(January (9708)):41-48.
6. Talaat K.R., Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Rockman S., et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. Journal of Infectious Diseases 2010, 202(November (9)):1327-1337.
7. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Research 2004, 103(July (1-2)):91-95.
8. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. Journal of Clinical Microbiology 1999, 37(April (4)):937-943.
9. Walls H.H., Harmon M.W., Slagle J.J., Stocksdale C., Kendal A.P. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses. Journal of Clinical Microbiology 1986, 23(February (2)):240-245.
10. NIAID to begin trials of candidate H1N1 vaccines in children: independent monitoring committee gives go-ahead after initial review of safety data. http://www.niaid.nih.gov/news/newsreleases/2009/Pages/H1N1pedvax.aspx.
11. Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults. http://www.niaid.nih.gov/news/newsreleases/2009/Pages/H1N1TrialsResults.aspx.
12. Lee G.M., Greene S.K., Weintraub E.S., Baggs J., Kulldorff M., Fireman B.H., et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. American Journal of Preventive Medicine 2011, 41(August (2)):121-128.
13. Liang X.F., Li L., Liu D.W., Li K.L., Wu W.D., Zhu B.P., et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. New England Journal of Medicine 2011, 364(February (7)):638-647.
14. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. MMWR. Morbidity and Mortality Weekly Report 2010, 59(June (21)):657-661.
15. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(October (45)):7248-7255.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007 May, Office of Communication, Training and Manufacturers Assistance (HFM-40), Rockville, MD.
17. Griffin M.R., Monto A.S., Belongia E.A., Treanor J.J., Chen Q., Chen J., et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011, 6(8):e23085.
18. Chen W.H., Cross A.S., Edelman R., Sztein M.B., Blackwelder W.C., Pasetti M.F. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011, 29(April (16)):2865-2873.
19. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25(November (44)):7656-7663.
20. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. Journal of Infectious Diseases 2009, 200(July (2)):172-180.
21. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Archives of Internal Medicine 2006, 166(May (10)):1121-1127.
22. Licensure of a high-dose inactivated influenza vaccine for persons aged > or =65years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR. Morbidity and Mortality Weekly Report 2010, 59(April (16)):485-486.
23. Wood J.M., Major D., Heath A., Newman R.W., Höschler K., Stephenson I., et al. Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard. Vaccine 2012, 30(January (2)):210-217.
24. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(January (9708)):56-66.
25. Uno S., Kimachi K., Kei J., Miyazaki K., Oohama A., Nishimura T., et al. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: randomized controlled trial. Microbiology and Immunology 2011, (November (11)):783-789.
26. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375(January (9708)):49-55.
27. Pariani E., Boschini A., Amendola A., Poletti R., Anselmi G., Begnini M., et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011, 29(November (49)):9209-9213.
28. Zuccotti G.V., Pariani E., Scaramuzza A., Santoro L., Giani E., Macedoni M., et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabetic Medicine 2011, 28(December (12)):1530-1536.
29. Stroud C., Nadig L., Altevogt B.M. The 2009 H1N1 influenza vaccination campaign: summary of a workshop series 2010, The National Academies Press.
30. Robertson J.S., Nicolson C., Harvey R., Johnson R., Major D., Guilfoyle K., et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011, 29(February (9)):1836-1843.
31. Schmeisser F., Vodeiko G.M., Lugovtsev V.Y., Stout R.R., Weir J.P. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010, 28(March (12)):2442-2449.